SEC Form 4 · accession 0000914190-15-000362
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norman David Eansor
Officer — SVP - Novus Biologicals
Period of report
Aug 7, 2015
Accepted (ET)
Aug 20, 2015 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $108.49 | Aug 7, 2015 | A | 9,375 | A | — | Aug 7, 2022 | Common Stock | 9,375 | 9,375 | D |
| Restricted Stock UnitsF2,F1 | — | Aug 7, 2015 | A | 1,500 | A | — | — | Common Stock | 1,500 | 1,500 | D |
Explanation of responses
- F1Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.
- F2Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Remarks
This amendment is being filed solely to correct the number of options and restricted stock units granted on August 7, 2015 as initially reported on August 11, 2015.